Stricter blood glucose targets
have been recommended by the
UK’s National Institute for Health
and Care Excellence (NICE) in its
new suite of diabetes guidance
which aims to help reduce variation
in the management and care of the
condition.
The guidance covers type 1
diabetes in adults, type 1 and type
2 diabetes in children and young
people, and diabetic foot care.
With most adults with type 1
diabetes presently having HbA1c
scores that are above target levels,
they are at increased risk of longterm
potentially life-threatening
complications.
The new guidleines recommend
adults with type 1 diabetes achieve
a target HbA1c level of 48 mmol/
mol (6.5%) or lower and should
be offered multiple daily injection
basal–bolus insulin regimens.
CLICK HERE to access guidelines.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Aug 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Aug 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.